For the quarter ending 2025-09-30, AXSM had $22,256K increase in cash & cash equivalents over the period. $988K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 442,497 | - |
| Cost of revenue (excluding amortization and depreciation) | 35,149 | - |
| Research and development expense (reversal) recognized-Solriamfetol | 32,094 | - |
| Research and development expense (reversal) recognized-AXS-05 | 42,896 | - |
| Research and development expense (reversal) recognized-AXS-07 | 15,379 | - |
| Research and development expense (reversal) recognized-AXS-12 | 6,019 | - |
| Research and development expense (reversal) recognized-AXS-14 | 5,951 | - |
| Other research and development | 11,942 | - |
| General and administrative expense (excluding share-based compensation expense) | 44,623 | - |
| Selling and marketing expense (excluding share-based compensation expense) | 305,864 | - |
| Stock-based compensation expense | 23,103 | - |
| Loss in fair value of contingent consideration | 13,185 | - |
| Interest expense, net | -5,385 | - |
| Other segment items | 14,193 | - |
| Profit Loss | -47,229 | - |
| Adjustments and reconciling items | 0 | - |
| Net loss | -47,229 | -107,386 |
| Stock-based compensation expense | 23,103 | 47,919 |
| Amortization of intangible asset | 1,607 | 3,161 |
| Amortization of debt discount | 158 | 984 |
| Loss on debt extinguishment | 0 | -10,385 |
| Depreciation | 120 | 269 |
| Loss in fair value of contingent consideration | 13,185 | -6,590 |
| Gain from lease modification | 0 | 2,250 |
| Non-cash lease expense | 817 | 1,432 |
| Right-of-use asset amortization for finance lease | 684 | 949 |
| Change in operating lease liability | -182 | -191 |
| Accounts receivable, net | -2,318 | 56,824 |
| Inventories, net | 4,994 | 2,026 |
| Prepaid expenses and other current assets | 3,451 | 4,360 |
| Non-current inventory and other assets | 1,936 | 3,223 |
| Accounts payable | -37,401 | 19,631 |
| Accrued expenses and other current liabilities | 54,247 | 22,322 |
| Net cash used in operating activities | 1,046 | -75,798 |
| Purchases of equipment | 58 | 351 |
| Net cash used in investing activities | -58 | -351 |
| Proceeds from draw down of debt | 70,000 | 190,000 |
| Payment of debt issuance costs | 0 | 3,638 |
| Repayment of debt | 70,000 | 191,988 |
| Payments on principal portion of finance lease obligation | 664 | 919 |
| Proceeds from issuance of common stock upon financing | 9,946 | 52,283 |
| Cash paid for common stock issuance costs | 189 | 910 |
| Proceeds from issuance of common stock upon exercise of options and under employee stock purchase plan | 15,524 | 28,696 |
| Payment of contingent consideration | -2,507 | -4,488 |
| Payments of tax withholdings on stock awards | 842 | 5,224 |
| Net cash provided by financing activities | 21,268 | 63,812 |
| Net increase (decrease) in cash | 22,256 | -12,337 |
| Cash and cash equivalents at beginning of period | 315,353 | - |
| Cash and cash equivalents at end of period | 325,272 | - |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)